

Ann Arbor, Michigan, U.S. | June 18, 2026

Sartorius achieves LEED Gold certification for Ann Arbor site

- U.S. Green Building Council certifies site to excellence in international sustainability standards
- Significant investments in energy efficiency, low-emissions materials, renewable energy as well as water management
- Facility contributes to Sartorius' climate targets

The life science group Sartorius has received Leadership in Energy and Environmental Design (LEED) v4 Gold certification by the U.S. Green Building Council for its Center of Excellence for Bioanalytics in Ann Arbor, Michigan. The designation recognizes the site's high standards in sustainable construction and energy-efficient building operations.

Certification under the LEED framework is based on criteria such as energy efficiency, CO₂ emissions, water consumption, material selection, resource conservation and indoor environmental quality. To meet the stringent requirements, Sartorius made multi-million-dollar investments in the sustainability aspects of the brownfield facility's design and construction. Measures include the use of certified sustainable materials, low-emission materials, on-site solar power generation, energy-efficient building systems with advanced air filtration and CO₂ monitoring, as well as electric vehicle infrastructure. Additional features such as LED lighting and a storm runoff pond further support the building's overall performance.

"The LEED Gold certification represents a significant milestone for the Ann Arbor site and Sartorius, recognizing our efforts to integrate sustainability into our infrastructure and operations," said Maurice Phelan, President of Sartorius North America. "Designed with sustainability in mind from the outset, the facility contributes to Sartorius' climate targets, including the ambition to achieve net-zero emissions by 2045."

The site, which opened in 2024, represents a total investment of more than 100 million US dollars and serves as a hub for the development and manufacturing of bioanalytical instruments, associated reagents, consumables and software solutions used for biopharma applications. In addition, it provides particle validation services and produces microcarriers.

In total, Sartorius operates six production sites in North America located in Yauco, Puerto Rico; Ashland and Marlborough in Massachusetts; New Oxford, Pennsylvania; Fremont, California; and Ann Arbor, Michigan. The company employs around 2,600 people across these locations, as well as its regional headquarters in Bohemia, New York, and its sales office in Newark, Delaware.

A profile of Sartorius

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Germany-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.

Visit our [newsroom](#) or follow Sartorius on [LinkedIn](#).

Contact

Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com